Shire plc has announced that the FDA has approved Midayis (mixed salts of a single-entity amphetamine product), a once-daily treatment...
Bone Therapeutics the cell therapy company addressing unmet medical needs in orthopedics and Medsenic, a privately held, clinical stage biopharmaceutical company incorporated in France and specialized in the development of optimized formulations of arsenic salts and their application in inflammatory conditions and other potential new indications, announce the signature of a binding contribution agreement to combine the operations of both companies by means of a share for share exchange, subject to the approval of the shareholders' meeting
Containing relevant Learning Zones, guidelines, trials and news.
Shire plc announces that it has reached an agreement with the FDA on a clear regulatory path for SHP 465...
Treatment of magnesium deficiency in hypomagnesaemia. Prevention of recurrent seizures in eclampsia.
Shire has announced positive topline results from a four-week randomized, double-blind, multicenter, parallel-group, placebo-controlled, forced-dose titration, efficacy and safety study,...